alexa
Reach Us +1-217-403-9671
?New? Drugs And International Regulatory Mechanisms | 8291
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

?New? drugs and international regulatory mechanisms

International Conference and Exhibiton on Pharmaceutical Regulatory Affairs

S. V. Eswaran

ScientificTracks Abstracts: JBB

DOI: 10.4172/0975-0851.1000107

Abstract
?Th e big players? continue to dominate the medicinal scene and such parameters are important when ?incurable? diseases set in. Prevention rather than ?treatment? of diseases needs to be emphasized. Interactions between hitherto undetected disease causing proteins (?small players?) are being targeted, whereby newer and better drugs are awaited in the forthcoming era of personalized medicine. Anti-fungals based on ?Click? reaction have been developed by the author. Fift y fi ve years since the discovery of the last vitamin, Pyrroloquinoline quinone (PQQ) is now recognized as the 14 th vitamin. To be useful as a vitamin, it has to available at low cost. Th e author?s work on ?true nitrene? based homo and hetero bifunctional crosslinkers for proteomics and lipidomics could be useful for chemical crosslinking-mass spectrometry based rapid and reliable high throughput screening (HTS) of large number of samples routinely. Soluble Fullerenes and SWCNT developed in my laboratory have been shown to be compatible with blood for nano- drug delivery. Norms for drug approvals becoming very stringent worldwide, discovery of new drug entities has now become very diffi cult. As ways are found for overcoming these, many issues arise, which need to be adjudged in an equitable and fair manner. Serving as a ?Local Commisioner? in cases of drug fi rms at an international level has been a learning experience for the author. Th e use of modern instrumentation for regulatory purposes is to be strongly advocated. Open Source Drug Discovery (OSDD), a laudable initiative has also provided the author much needed stimulus
Biography
Dr S. V. Eswaran, Head, Chemistry Department and Dean, (Academics), St. Stephen?s College, University of Delhi, Delhi and has taught there for 42 years. Served as Principal, Deshbandhu College, Delhi for two years and as a member for many national committees. Ph. D., Delhi, 1973; Post-Doc. Max Planck, Munich, 1976-77; Heidelberg, Karlsruhe, 1984; Goettingen, 1997, Germany; TU, Delft, Netherlands,1990; Ohio State University, 1997; Brown University, 2006, USA. Best teacher award, 2007; distinguished teacher award, 2009; DADD fellowship, 1976-77. Published 60 papers, granted many patents and supervised 4 Ph. D. and 21 M. sc/ M. Tech.. thesis.
Relevant Topics
Top